XtalPi is a biotech firm that uses artificial intelligence and computing to accelerate the development of new drugs. The company uses algorithms to predict the crystallized form a drug will take. This data enables XtalPi to work with other pharmaceutical companies to develop new drugs and create new patents.

XtalPi’s integrated, end-to-end technology platform ID4 efficiently delivers validated small molecule preclinical candidates. The company also has an antibody discovery platform, XupremAb™, that combines the best of wet-lab techniques and cutting-edge AI technology. As of 2023, XtalPi has secured USD 400 million in a Series D financing round, bringing its valuation to over RMB 13 billion (USD 2 billion).